Company intelligence / Profile preview

Alfa Rhythm

Boston, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

IMCIVREE (setmelanotide) is commercially approved for rare genetic obesity disorders including POMC, LEPR, and PCSK1 deficiencies, Bardet-Biedl, and Alström syndromes. Phase 3 completed in hypothalamic obesity with 20% placebo-adjusted weight loss; Phase 2 oral cetmelanotide data expected Q3 2025; ongoing studies in Prader-Willi syndrome.[1][2]

Therapeutic areas: EndocrinologyRare DiseasesMetabolic Disorders
Modalities: PeptideSmall molecule
Industry: Biotech

Partnerships

LG Chem Ltd.Ipsen Pharma S.A.S.Camurus ABRareStone Group Ltd.

Beyond the preview

Go deeper on Alfa Rhythm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alfa Rhythm.

Explore the full profile